medigraphic.com
ISSN 2307-2113 (Electronic)
Revista Cubana de Información en Ciencias de la Salud (ACIMED)

2014, Number 3

<< Back Next >>

Revista Cubana de Información en Ciencias de la Salud (ACIMED) 2014; 25 (3)

Tuberculosis, Bacillus Calmette-Guérin (BCG) and tuberculosis vaccines: a patent analysis

Díaz PM, Guzmán SMV, Giráldez RR, Armas PD, Rodríguez FRJ, Carrillo CHA

Language: Spanish
References: 18
Page: 259-269
PDF size: 190.48 Kb.


ABSTRACT

As an object of study, the relationship between tuberculosis, Bacillus Calmette-Guérin and tuberculosis vaccines starts from the fact that the only vaccine currently available to prevent tuberculosis in humans is BCG, and its improvement or the development of new vaccines is a key strategy to control the disease. The present study intends to make a contribution to such important research from a patent metrics perspective. Its purpose is to conduct a metric analysis allowing to describe the productivity of patents for tuberculosis, Bacillus Calmette-Guérin and tuberculosis vaccines in a given time period. For the productivity study, an analysis was carried out of the behavior of temporal and geographic indicators in the domain, using techniques and tools suitable for patent documents. Research into tuberculosis as an infectious communicable disease has received great attention. Until recently, tuberculosis was considered to be a health problem in the developing world. However, after its re-emergence, research has been mainly conducted in developed countries. But such efforts have not been in proportion to research aimed at developing a new generation of vaccines against the disease, and there are no new patents supporting them.


REFERENCES

  1. Morales A, Eidinger D, Bruce AW. Intracavity bacillus Calmette-Guérin in the treatment of superficial bladder tumors. J Urol. 1976;116:180-3.

  2. Morales A, Wilson JL, Pater JL, Loeb M. Cytoreductive surgery and systemic bacillus Calmette-Guérin therapy in metastatic renal cancer: a phase II trial. J Urol. 1982;127:230-5.

  3. Edwards ML, Goodrich JM, Muller D, Pollack A, Ziegler JE, Smith DW. Infection with Mycobacterium avium-intracellulare and the protective effects of Bacille Calmette-Guérin. J Infect Dis. 1982;145:733-41.

  4. Cole ST. Deciphering the biology of Mycobacterium Tuberculosis from the complete genome sequence. Nature. 1998;393(6685):537-44.

  5. Lozes E, Huygen K, Content J, Denis O, Montgomery DL, Yawman AM, et al. Immunogenicity and efficacy of a Tuberculosis DNA vaccine encoding the components of the secreted antigen 85 complex. Vaccine. 1997;15:830-3.

  6. Denis O, Tanghe A, Palfliet K, Jurion F, Van den Berg TP, Vanonckelen A, et al. Vaccination with plasmid DNA encoding mycobacterial antigen 85A stimulates a CD4+ and CD8+ T-cell epitopic repertoire broader than that stimulated by Mycobacterium Tuberculosis H37Rv infection. Infect Immun. 1998;66(4):1527-33.

  7. Baldwin SL. Immunogenicity and protective efficacy of DNA vaccines encoding secreted and non-secreted forms of Mycobacterium tuberculosis Ag85A. Tuber Lung Dis. 1999;79:251-9.

  8. Li Z, Howard A, Kelley C, Delogu G, Collins F, Morris S. Immunogenicity of DNA vaccines expressing tuberculosis proteins fused to tissue plasminogen activator signal sequences. Infect Immun. 1999;67:4780-6.

  9. Mohd-Nor N, Acosta A, Sarmiento ME. The art and science of tuberculosis vaccine development. Oxford University Press. Penerbit Universiti Sains Malaysia; 2010. p. 634.

  10. Guzmán MV, Carrillo H, Jiménez JL. Bioinformetric studies on TB vaccines research. En: The art and science of Tuberculosis vaccine development. Oxford University Press. Penerbit Universiti Sains Malaysia; 2010. p. 425-41.

  11. Sierra VG. Is a new Tuberculosis vaccine necessary and feasible? A Cuban opinion. Tuberculosis (Edinb). 2006;86(3-4):169-78.

  12. Ly LH, McMurray DN. Tuberculosis: vaccines in the pipeline. Expert Rev Vaccines. 2008;7(5):635-50.

  13. McShane H. Vaccine strategies against tuberculosis. Swiss Med Wkly. 2009;19:1-6.

  14. Srivastava R, Kumar D, Srivastava BS. Mycobacterium Tuberculosis specific DNA fragment. Washington, DC: USPTO 6,114,514; 2001.

  15. Mori T. Recent Trends in Tuberculosis, Japan. Emerging Infectious Diseases Journal. 2000;6(6):566-8.

  16. World Health Organization. Global Tuberculosis control - surveillance, planning, financing (WHO Report 2009). World Health Organization. WHO/HTM/TB/2009.411 [citado: 20 de octubre de 2011]. Disponible en: http://www.who.int/tb/publications/global_report/2009/en/index.html

  17. Dwivedi A. Tuberculosis-India to treat all MDR-TB cases by 2010: WHO Official Says. The Seoul Times. Wednesday, September 24, 2008. World Health Organization (WHO). 2008.

  18. World Health Organization, Communicable Diseases. DOTS prevents TB deaths in India. In: Health a key to prosperity. Geneva WHO [citado: 20 de octubre de 2011]. Disponible en http://www.who.int/inf-new/tuber3.htm




2020     |     www.medigraphic.com